We are live on ! Find out more
SSC

Spruce Street Capital Portfolio holdings

AUM $510M
This Fund
S&P 500
This Quarter Est. Return
+66.43%
1 Year Est. Return
–
3 Year Est. Return
–
5 Year Est. Return
–
10 Year Est. Return
–
AUM
$303M
AUM Growth
–
Cap. Flow
+$250M
Cap. Flow %
82.69%
Top 10 Hldgs %
70.8%
Holding
27
New
27
Increased
–
Reduced
–
Closed
–
Avg Time Held
0 quarters
Top 10 Avg Time Held
0 quarters
Top 20 Avg Time Held
0 quarters

Top Buys

Rank Stock Value
1
CDTX
Cidara Therapeutics
CDTX
+$37.5M
2
RLAY icon
Relay Therapeutics
RLAY
+$21.3M
3
PCVX icon
Vaxcyte
PCVX
+$17.9M
4
LBRX
LB Pharmaceuticals
LBRX
+$17.6M
5
KNSA icon
Kiniksa Pharmaceuticals
KNSA
+$17.4M

Top Sells

No sells this quarter

Sector Composition

Rank Sector Weight
1 Healthcare 100%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow Held Since
CDTX
1
DELISTED
Cidara Therapeutics
CDTX
$51.3M 16.95%
+232,269
New +$37.5M
2025 Q4
0 quarters
RLAY icon
2
Relay Therapeutics
RLAY
$3.92B
$25.2M 8.34%
+2,984,125
New +$21.3M
2025 Q4
0 quarters
LBRX
3
LB Pharmaceuticals
LBRX
$1.2B
$22.4M 7.4%
+1,005,593
New +$17.6M
2025 Q4
0 quarters
RLMD icon
4
Relmada Therapeutics
RLMD
$362M
$19.7M 6.52%
+4,086,181
New +$13.7M
2025 Q4
0 quarters
PCVX icon
5
Vaxcyte
PCVX
$10.6B
$18.5M 6.1%
+400,360
New +$17.9M
2025 Q4
0 quarters
KNSA icon
6
Kiniksa Pharmaceuticals
KNSA
$6.22B
$17.9M 5.93%
+434,982
New +$17.4M
2025 Q4
0 quarters
EYPT icon
7
EyePoint Inc
EYPT
$293M
$17.9M 5.93%
+981,543
New +$13.9M
2025 Q4
0 quarters
SVRA icon
8
Savara
SVRA
$1.01B
$14.5M 4.8%
+2,411,093
New +$11.8M
2025 Q4
0 quarters
ERAS icon
9
Erasca
ERAS
$5.61B
$14.5M 4.78%
+3,889,632
New +$10.9M
2025 Q4
0 quarters
DNTH icon
10
Dianthus Therapeutics
DNTH
$4.61B
$12.3M 4.05%
+297,437
New +$11.5M
2025 Q4
0 quarters
SRZN icon
11
Surrozen
SRZN
$349M
$9.76M 3.23%
+432,040
New +$6.99M
2025 Q4
0 quarters
OCUL icon
12
Ocular Therapeutix
OCUL
$1.66B
$9.52M 3.14%
+783,999
New +$9.52M
2025 Q4
0 quarters
SABS icon
13
SAB Biotherapeutics
SABS
$271M
$8.22M 2.72%
+2,198,502
New +$7.23M
2025 Q4
0 quarters
IKT icon
14
Inhibikase Therapeutics
IKT
$275M
$7.34M 2.43%
+3,581,603
New +$5.7M
2025 Q4
0 quarters
ELVN icon
15
Enliven Therapeutics
ELVN
$3B
$6.87M 2.27%
+446,084
New +$8.89M
2025 Q4
0 quarters
NERV icon
16
Minerva Neurosciences
NERV
$152M
$6.66M 2.2%
+1,655,500
New +$6.15M
2025 Q4
0 quarters
ABVX
17
Abivax
ABVX
$7.69B
$6.62M 2.19%
+49,119
New +$5.36M
2025 Q4
0 quarters
HELP
18
Helus Pharma Inc. Common Stock
HELP
$862M
$6.3M 2.08%
+770,000
New +$4.96M
2025 Q4
0 quarters
KALV
19
DELISTED
KalVista Pharmaceuticals
KALV
$6.27M 2.07%
+387,968
New +$5.14M
2025 Q4
0 quarters
ENTA icon
20
Enanta Pharmaceuticals
ENTA
$364M
$6.15M 2.03%
+389,687
New +$4.95M
2025 Q4
0 quarters
ANRO icon
21
Alto Neuroscience
ANRO
$956M
$3.97M 1.31%
+222,844
New +$2.81M
2025 Q4
0 quarters
LONA
22
LeonaBio Inc
LONA
$54.2M
$2.98M 0.98%
+393,701
New +$1.8M
2025 Q4
0 quarters
CNTA
23
DELISTED
Centessa Pharmaceuticals
CNTA
$1.95M 0.64%
+77,997
New +$1.98M
2025 Q4
0 quarters
ALEC icon
24
Alector
ALEC
$232M
$1.74M 0.58%
+1,117,986
New +$1.98M
2025 Q4
0 quarters
LXEO icon
25
Lexeo Therapeutics
LXEO
$265M
$1.74M 0.57%
+175,000
New +$1.6M
2025 Q4
0 quarters
1
2

Similar funds

AG
Alibaba Group Causeway Bay, Hong Kong $509M AUM 25.62% 1-Year Est. Return
TGY2IT
Timothy G. Youngquist 2020 Irrevocable Trust Fort Myers, Florida $510M AUM
AWM
Aries Wealth Management Portland, Maine $509M AUM 25.6% 1-Year Est. Return
RPSA
Richard P. Slaughter Associates Austin, Texas $510M AUM 21.97% 1-Year Est. Return
WCP
Welch Capital Partners Harrison, New York $510M AUM 23.67% 1-Year Est. Return
MPPLM
Midwest Professional Planners Ltd (MPPL) Wausau, Wisconsin $510M AUM 49.02% 1-Year Est. Return
MVP
Medina Value Partners Los Angeles, California $510M AUM 26.16% 1-Year Est. Return
NLP
Next Level Private Harrison, New York $511M AUM 30.94% 1-Year Est. Return

Spruce Street Capital's Q4 2025 Portfolio in Review

Q4 2025 is the first quarter with a 13F filing on record for Spruce Street Capital, which disclosed 27 positions worth $303M. Its ten largest holdings account for 71% of the portfolio.

Its largest position is Cidara Therapeutics: 232,269 shares worth $51.3M.

By sector, the portfolio is most concentrated in Healthcare at 100% of assets.

  • Spruce Street Capital's largest Q4 2025 buy was Cidara Therapeutics: 232,269 shares worth $51.3M.
  • Spruce Street Capital's ten largest holdings make up 71% of its $303M portfolio in Q4 2025.
  • Spruce Street Capital disclosed 27 positions in Q4 2025, its first 13F filing on record.

Based on Spruce Street Capital's 13F filing for Q4 2025, filed 13 Feb 2026.